NCT07365319 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07365319
Title	A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (TeLuRide-008)
Acronym	TeLuRide-008
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Eikon Therapeutics
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + EIK1001 + Pembrolizumab + Pemetrexed Disodium Carboplatin + EIK1001 + Nab-paclitaxel + Pembrolizumab Carboplatin + EIK1001 + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + EIK1001 + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST